Treatment outcomes for oropharyngeal cancer: findings from an institutional study
This study demonstrates excellent outcomes for HPV-positive OPSCC, consistent with RTOG 0129 and 1016 trials. RCT, particularly with 3-weekly cisplatin, was associated with superior survival outcomes, with an absolute 15% difference in 5-year OS in HPV-positive patients compared with weekly cisplatin. RCT remains the standard of care, while HPV-negative disease continues to pose a major therapeutic challenge.
Authors
- Sameh Geha (ORCID: https://orcid.org/0000-0002-4851-9034)
- C Wang
- Mathieu Belzile
- Jérôme Costisella (ORCID: https://orcid.org/0009-0004-8703-2861)
- Isabelle Gauthier
- Ayman Jafar Oweida
- Benoit Emond-Guilbert
- Pierre-Hugues Fortier
Institutions
- Université de Sherbrooke (CA)
- Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean (CA)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-16
- DOI
- https://doi.org/10.3389/fonc.2026.1720966
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00